FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2017 to Q4 2025

Type / Class
Equity / Common Shares, no par value
Symbol
FENC on Nasdaq
Shares outstanding
34,309,263
Price per share
$7.70
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
13,863,242
Total reported value
$129,757,954
% of total 13F portfolios
0%
Share change
+261,332
Value change
+$2,614,052
Number of holders
83
Price from insider filings
$7.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Southpoint Capital Advisors LP 8% $21,135,329 2,744,741 Southpoint Master Fund, LP 31 Dec 2025
Solas Capital Management, LLC 8.2% +17% $12,807,729 +$1,862,809 2,250,919 +17% Solas Capital Management, LLC 31 Dec 2024
Rosalind Advisors, Inc. 7.5% $19,439,222 2,076,840 Rosalind Advisors, Inc. 30 Sep 2025
DG Capital Management, LLC 4.1% $6,342,597 1,114,692 DG Capital Management, LLC 31 Dec 2024

As of 30 Sep 2025, 83 institutional investors reported holding 13,863,242 shares of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC). This represents 40% of the company’s total 34,309,263 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) together control 39% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Southpoint Capital Advisors LP 12% 4,077,214 0% 1% $38,162,723
Solas Capital Management, LLC 6.4% 2,187,902 -2% 12% $20,478,763
Rosalind Advisors, Inc. 6.1% 2,076,840 +1.5% 7.1% $19,439,222
BlackRock, Inc. 3.5% 1,211,806 -1.2% 0% $11,342,505
VANGUARD GROUP INC 2.8% 955,764 -1.2% 0% $8,945,951
AIGH Capital Management LLC 2% 681,501 +51% 2.2% $6,378,850
STATE STREET CORP 0.99% 341,201 +1.4% 0% $3,193,641
TANG CAPITAL MANAGEMENT LLC 0.98% 334,593 +1530% 0.12% $3,131,790
GEODE CAPITAL MANAGEMENT, LLC 0.88% 300,772 -1.3% 0% $2,815,225
MORGAN STANLEY 0.68% 232,402 -8.6% 0% $2,175,283
HARBERT FUND ADVISORS, INC. 0.52% 177,815 -38% 11% $1,664,348
GENDELL JEFFREY L 0.41% 139,559 -0.11% 0.02% $1,306,272
NORTHERN TRUST CORP 0.38% 130,553 -0.7% 0% $1,221,976
Lion Point Capital, LP 0.36% 123,000 -37% 6.5% $1,151,280
CITADEL ADVISORS LLC 0.31% 107,496 +130% 0% $1,006,163
JANE STREET GROUP, LLC 0.21% 72,631 +45% 0% $679,826
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.17% 57,249 -6.6% 0% $535,851
Bank of New York Mellon Corp 0.15% 52,278 +0.9% 0% $489,325
Hartford Financial Management Inc. 0.15% 50,646 0% 0.13% $474,047
RHUMBLINE ADVISERS 0.1% 33,522 -1.1% 0% $313,757
BARCLAYS PLC 0.1% 33,038 -17% 0% $309,236
STATE OF WISCONSIN INVESTMENT BOARD 0.09% 32,100 +38% 0% $300,456
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.09% 30,700 +27% 0.01% $287,352
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.08% 27,055 0% 0% $253,235
GOLDMAN SACHS GROUP INC 0.08% 26,490 +66% 0% $247,946

Institutional Holders of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 51,163 $393,956 +$8 $7.70 5
2025 Q3 13,863,242 $129,757,954 +$2,614,052 $9.36 83
2025 Q2 13,599,927 $112,877,891 +$2,365,581 $8.30 77
2025 Q1 13,390,166 $81,552,976 -$1,522,792 $6.09 68
2024 Q4 16,048,764 $101,424,546 +$7,283,101 $6.32 64
2024 Q3 14,931,283 $74,650,166 +$2,539,947 $5.00 62
2024 Q2 14,360,522 $87,742,748 -$6,402,237 $6.11 62
2024 Q1 14,487,904 $161,105,911 -$6,099,282 $11.12 64
2023 Q4 15,010,968 $168,423,713 +$8,238,895 $11.22 55
2023 Q3 14,291,968 $107,334,991 +$1,444,870 $7.51 54
2023 Q2 14,066,767 $124,212,045 +$9,438,707 $8.83 54
2023 Q1 13,040,023 $108,481,973 +$4,197,539 $8.32 53
2022 Q4 12,451,231 $119,532,387 -$8,641,346 $9.60 42
2022 Q3 11,367,575 $92,077,143 +$913,826 $8.10 29
2022 Q2 11,273,521 $63,103,949 -$835,989 $5.63 24
2022 Q1 11,437,604 $64,049,354 +$542,291 $5.60 24
2021 Q4 11,346,536 $49,924,524 -$2,427,096 $4.40 26
2021 Q3 11,649,016 $109,719,412 -$3,040,624 $9.42 30
2021 Q2 12,077,739 $88,042,799 -$14,218,632 $7.29 36
2021 Q1 14,373,653 $89,259,363 -$593,443 $6.21 49
2020 Q4 14,462,317 $107,736,409 +$5,043,456 $7.45 48
2020 Q3 13,830,913 $83,811,378 -$1,125,208 $6.06 51
2020 Q2 13,870,610 $115,816,682 +$37,949,605 $8.35 53
2020 Q1 9,462,229 $56,207,308 +$983,452 $5.94 25
2019 Q4 9,292,337 $60,284,409 -$38,066 $6.48 26
2019 Q3 8,465,309 $40,716,816 -$1,958,704 $4.81 21
2019 Q2 8,988,085 $35,952,664 -$3,100,726 $4.00 25
2019 Q1 9,638,104 $46,743,906 -$525,691 $4.85 44
2018 Q4 9,742,725 $62,159,250 +$1,863,710 $6.38 45
2018 Q3 9,435,050 $77,373,042 -$276,921 $8.20 45
2018 Q2 9,392,799 $98,080,873 +$18,177,598 $10.44 43
2018 Q1 7,623,491 $92,186,011 +$4,858,661 $12.09 21
2017 Q4 6,949,133 $69,588,032 +$18,006,732 $10.00 16
2017 Q3 5,214,611 $57,723,043 +$57,723,043 $11.03 10